ArticleOncology letters2026
Update on the clinical features, treatment and histogenesis of combined hepatocellular-cholangiocarcinoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunohistochemistry-Based Molecular Classification of Muscle-Invasive Bladder Urothelial Carcinoma: Survival Trends Across Molecular Subtypes.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined hepatocellular-cholangiocarcinoma (CHC) is a rare subtype of primary liver cancer with histological features of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The clinicopathological features, treatment and histogenesis of CHC remain to be elucidated due to its low morbidity. In total, 26 patients with CHC, 901 patients with HCC and 40 patients with ICC were included in the present retrospective study and their clinicopathological characteristics and prognoses were compared. The treatment patterns of postoperative CHC recurrence were analyzed. Immunohistochemistry for the hepatic progenitor cell (HPC) markers CD90 and epithelial cell adhesion molecule (EpCAM) was performed to investigate the origin of CHC. CHC demonstrated clinicopathological features of both HCC and ICC. Patients with CHC had similar overall survival (OS) and disease-free survival (DFS) rates to those with ICC, but all had significantly lower survival rates compared with those with HCC. Univariate analysis revealed that α-fetoprotein, carbohydrate antigen 19-9, carcinoembryonic antigen, tumor size, macrovascular invasion and lymph node metastasis were risk factors for both OS and DFS. Most patients with recurrent CHC received comprehensive treatment. Immunohistochemistry revealed that patients with CHC exhibited high expression levels of CD90 and EpCAM. In conclusion, compared with patients with HCC and ICC, patients with CHC appear to have intermediate clinical characteristics. Comprehensive postoperative therapy may be a promising strategy for patients with CHC. The high expression level of HPC markers in tumor tissues suggests that CHC may originate from HPCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.